Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Slides:

Advertisements

Similar presentations

DNA damage foci in irradiated cells.

Advertisements

BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25). BCR–ABL1 B-ALLs feature DNA methylation and expression signatures.

PARPi combinations against HR-proficient tumors.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Antitumor activity of BAY in patient-derived tumor models.

Reduction of Sca-1 increases PPARγ expression.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

Mechanisms of PARPi resistance in HR-deficient cells.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Epigenetic regulation of miR-193b in liposarcomagenesis.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Alterations related to androgen signaling.

Core promoter methylation in mediators of adipogenesis.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

GATC sites where methylation changes over time correspond to a change in gene expression in a dam mutant. GATC sites where methylation changes over time.

Cancer mutations in enriched RBP motifs.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

Expression of selected intergenic regions in response to increasing concentrations of XIP. qRT-PCR analysis of gene expression was performed with strain.

NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Influence of RdDM on DCL4 Transcript Isoform Expression.

PTENP1 sensitizes renal cancer cells to chemotherapy.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Protein expression profile in a dasatinib-resistant cell line.

A, scatterplots of qMSP analysis of candidate genes promoters in the prevalence screen cohort, which consisted of 55 HNSCC tumor tissue samples and 37.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

M-Wnt and E-Wnt cells cluster tightly with claudin-low and basal-like breast tumors, respectively, by microarray analysis. M-Wnt and E-Wnt cells cluster.

Active AR signaling in enzalutamide-resistant xenograft tumors.

EN1 expression in breast cancer and clinical outcome.

A, unsupervised clustering of all BRCA1 (red), BRCA2 (blue), and sporadic (green) breast tumors of our collection using the regions reported as discriminative.

Plasma and tissue EGFR allele analyses.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Discovered and replicated positive correlation between miR-193b

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. Platinum-based chemotherapy.

ROR1 expression is inversely correlated to Wnt5A/ROR2.

Prevalence of germline T790M.

Location of the ER mutations and frequencies per cohort.

Change in FES uptake in the tumor during fulvestrant treatment.

A and B, two blocks from the original specimen used for TMA demonstrated areas with varying patterns of ALK rearrangement and KRAS mutation status. A and.

Frequently mutated genes in colorectal cancer.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Molecular definitions of lung adenocarcinoma subtypes.

P53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo CreER angiosarcoma. p53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Trastuzumab resistance siRNA screen identifies PPM1H.

Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1.

Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.

Germline variants influencing primary tumor type.

ERCC2 mutation mapping and distribution across tumor types.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

H3K36me3 is not essential for LEDGF and MLL target gene occupancy.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Driver pathways and key genes in OSCC

Integrated analysis of gene expression and copy number alterations.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

CREB1 binds at the proximal region of the TGFB2 promoter and induces its transcriptional activation. CREB1 binds at the proximal region of the TGFB2 promoter.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Presentation transcript:

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Red indicates tumors sensitive to cisplatin. Tumors with a germline mutation in BRCA1 or BRCA2 are excluded in A and B but included in C, represented as triangles. In B and C, BRCA1 transcript levels measured by qRT-PCR were z-transformed and combined by centering the values and dividing by the standard deviation within each trial. A, BRCA1 transcripts in resistant and sensitive tumors in the Cisplatin-2 cohort. B, BRCA1 expression in tumors by methylation status of the BRCA1 promoter region in the combined Cisplatin-1 and Cisplatin-2 cohorts. C, relationship of BRCA1 transcript level and NtAI in the combined Cisplatin-1 and Cisplatin-2 cohorts. Nicolai J. Birkbak et al. Cancer Discovery 2012;2:366-375 ©2012 by American Association for Cancer Research